{"id":735,"date":"2002-12-01T12:03:00","date_gmt":"2002-12-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/nochmals-arzneitherapien-an-der-obergrenze-der-finanziellen-belastbarkeit"},"modified":"2002-12-01T12:03:00","modified_gmt":"2002-12-01T11:03:00","slug":"nochmals-arzneitherapien-an-der-obergrenze-der-finanziellen-belastbarkeit","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/nochmals-arzneitherapien-an-der-obergrenze-der-finanziellen-belastbarkeit","title":{"rendered":"Nochmals: Arzneitherapien an der Obergrenze der finanziellen Belastbarkeit"},"content":{"rendered":"<p>Wir haben uns in diesem Jahr ausf\u00fchrlich an Beispielen aus der H\u00e4matologie, Onkologie und Gastroenterologie mit kostenintensiven Arzneimitteln besch\u00e4ftigt. (AMB 2002, 36, 25; 33 und 65). Diese Hauptartikel bezogen sich auf Vortr\u00e4ge eines von der Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) organisierten Themenschwerpunkts \u201dArzneitherapien an der Obergrenze der finanziellen Belastbarkeit\u201d anl\u00e4\u00dflich des 26. Interdisziplin\u00e4ren Forums der [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben uns in diesem Jahr ausf\u00fchrlich an Beispielen aus der H\u00e4matologie, Onkologie und Gastroenterologie mit kostenintensiven Arzneimitteln besch\u00e4ftigt. (AMB 2002, 36, 25; 33 und 65). Diese Hauptartikel bezogen sich auf Vortr\u00e4ge eines von der Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) organisierten Themenschwerpunkts \u201dArzneitherapien an der Obergrenze der finanziellen Belastbarkeit\u201d anl\u00e4\u00dflich des 26. Interdisziplin\u00e4ren Forums der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[268,1279,1358,1378,271,463,799,1615,1608,1612,1032,269,1878,204,1879,150,1267,1880,430,1145,292,465,1136,1394,111,1038,1137,115,114,1877,1143,1035,798,262,264],"class_list":["post-735","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-5-fluorouracil","tag-anaemie","tag-b-zell-lymphom","tag-b-zell-non-hodgkin-lymphom","tag-chemotherapie","tag-chronisch-entzuendliche-darmerkrankungen","tag-chronische-lymphatische-leukaemie","tag-erythropoese-stimulierende-wirkstoffe","tag-erythropoietin","tag-esa","tag-esomeprazol","tag-folinsaeure","tag-gela-studie","tag-hepatitis-c","tag-hypogammaglobulinaemie","tag-immunglobuline","tag-infliximab","tag-interferon","tag-kolonkarzinom","tag-kolorektales-karzinom","tag-lansoprazol","tag-m-crohn","tag-multiples-myelom","tag-non-hodgkin-lymphom","tag-omeprazol","tag-peginterferon-alfa-2b","tag-plasmozytom","tag-protonenpumpen-hemmer","tag-protonenpumpenhemmer","tag-quasar-studie","tag-rektumkarzinom","tag-ribavirin","tag-rituximab","tag-zytostatika","tag-zytostatische-therapie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=735"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/735\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}